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Abstract
Background: Malaria parasites are transmitted by Anopheles mosquitoes. Although several studies have identified
mosquito midgut surface proteins that are putatively important for Plasmodium ookinete invasion, only a few have
characterized these protein targets and demonstrated transmission-blocking activity. Molecular information about
these proteins is essential for the development of transmission-blocking vaccines (TBV). The aim of the present
study was to test three monoclonal antibodies (mAbs), A-140, A-78 and A-10, for their ability to recognize antigens
and block oocyst infection of the midgut of Anopheles albimanus, a major malaria vector in Latin America.
Method: Western-blot of mAbs on antigens from midgut brush border membrane vesicles was used to select
antibodies. Three mAbs were tested by membrane feeding assays to evaluate their potential transmission-blocking
activity against Plasmodium berghei. The cognate antigens recognized by mAbs with oocyst-reducing activity were
determined by immunoprecipitation followed by liquid chromatography tandem mass spectrometry.
Results: Only one mAb, A-140, significantly reduced oocyst infection intensity. Hence, its probable protein target in
the Anopheles albimanus midgut was identified and characterized. It recognized three high-molecular mass proteins
from a midgut brush border microvilli vesicle preparation. Chemical deglycosylation assays confirmed the peptide
nature of the epitope recognized by mAb A-140. Immunoprecipitation followed by proteomic identification with
tandem mass spectrometry revealed five proteins, presumably extracted together as a complex. Of these, AALB007909
had the highest mascot score and corresponds to a protein with a myosin head motor domain, indicating that the
target of mAb A-140 is probably myosin located on the microvilli of the mosquito midgut.
Conclusion: These results provide support for the participation of myosin in mosquito midgut invasion by Plasmodium
ookinetes. The potential inclusion of this protein in the design of new multivalent vaccine strategies for blocking
Plasmodium transmission is discussed.
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Background
Malaria kills approximately 584,000 people annually,
mainly children under five years of age [1]. Plasmodium
parasites are the causative agents of this disease and are
transmitted to humans by Anopheles mosquitoes. During
the life cycle of Plasmodium, sexual stage gametocytes
in humans pass to Anopheles mosquitoes in a blood
meal. Male and female gametes then egress from their
host red blood cell, and fertilized female macrogametes
transform into motile ookinetes that can invade the
mosquito midgut epithelium. Upon reaching the basal
lamina, ookinetes develop into oocysts. Thousands of
sporozoites form in mature oocysts and then escape into
the hemocoel. From there they can invade the salivary
glands and be inoculated into new vertebrate hosts dur-
ing subsequent feeding events [2].
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Without the successful development of malaria parasites
in the mosquito vector midgut, parasite transmission to
vertebrates is not possible [3]. Transmission-blocking
vaccines (TBV), proposed as a complementary strategy to
combat malaria, target either the parasite stages that de-
velop in the mosquito midgut or their cognate midgut
receptors. By interfering with the molecular interactions
necessary for the fertilization of gametes, the ookinete
invasion of the midgut epithelium, or the ookinete-to-
oocyst transition, these TBVs could prevent malaria trans-
mission [4] and thus serve as an important tool for
malaria elimination and eradication [5].
Some molecules on the apical surface of the An. gam-
biae midgut are known to play an important role in
ookinete invasion, including a conserved O-linked glycan
on midgut glycoproteins [6], several annexin-like protein
isoforms [7], aminopeptidase N1 (APN1) [8], sulfated
proteoglycans [9], carboxypeptidase B (CPB) [10, 11],
Croquemort scavenger receptors (SCRBQ2) [12], a se-
creted glycoconjugate of unknown function (SGU) [13],
and the enolase binding protein (EBP) [14]. However,
there is still limited information about the molecular
structure of midgut proteins that are potentially unique
to mosquitoes in the Americas. One such mosquito, An.
albimanus, is a major malaria vector in Latin America
[15]. The aim of the present study was to test three
monoclonal antibodies (mAbs), A-78, A-10 and A-140,
for their ability to recognize antigens and block oocyst
infection of the midgut of An. albimanus. We herein re-
port the transmission-blocking activity of monoclonal
antibody (mAb) A-140 and the characterization of its
probable target antigen in the midgut of An. albimanus.
Methods
Ethics statement
This study was authorized by the Ethics in Animal
Care committee of the Mexican National Institute of
Public Health (INSP: Instituto Nacional de Salud
Pública, reference number CI:939).
Mosquitoes
Female An. albimanus mosquitoes (3-5 day-old) from
the white striped colony [16] at the insectary of INSP
were maintained in standard rearing conditions (25 °C
and 80 % humidity) and fed with cotton pads soaked in
4 % sucrose water solution. Midguts from groups of fe-
male mosquitoes were dissected in PBS supplemented
with 1X complete EDTA-free protease inhibitor cocktail
(Roche) and stored at -70 °C.
Brush border membrane vesicle (BBMV) preparation
BBMV were obtained from frozen midguts (n = 1,000) as
described previously [17], with some modifications.
Briefly, midguts were transferred to 500 μl of microvilli
buffer (300 mM mannitol, 20 mM Tris-HCl, 5 mM
EGTA at pH 7.4, 2 mM dithiothreitol, 0.5 mM phenyl-
metylsulfonyl fluoride, and 2× complete EDTA-free pro-
tease inhibitor cocktail; Roche) on ice. The midguts
were homogenized by 10 cycles of 30 s each (with 30-
second intervals) with a Dounce homogenizer. Four
hundred and 50 μl of microvilli buffer and 50 μl of
250 mM MgCl2 were added and mixed by vortexing.
After 20 min of incubation on ice, the sample was cen-
trifuged at 3,500 g and 4 °C for 15 min. The supernatant
was collected and the pellet suspended in 500 μl of
microvilli buffer, then extracted twice as aforementioned.
Supernatants from all extractions were pooled and sub-
jected to ultracentrifugation at 30,000 g and 4 °C for 1 h.
The supernatant was discarded and the pellet was sus-
pended in 300 μl of PBS. To verify BBMV enrichment,
1 μl of the suspended pellet solution and 1 μl of the ini-
tial crude homogenate were assayed for aminopeptidase
specific activity using L-leucine-p-nitroanilide as sub-
strate [18]. Protein quantification of the BBMV was per-
formed using a BCA protein assay Kit (Pierce, Rockford
IL). The BBMV preparation was stored at -70 °C to await
further use.
Monoclonal antibody production
Anopheles albimanus mosquito midguts were dissected
and snap-frozen in sterile PBS containing a protease inhibi-
tor cocktail (P8340, Sigma Chemical Co.) To produce
mAbs we followed the protocol described by Niebuhr et al.
[19]. Hybridoma cells were generated by fusion of cells ob-
tained from the popliteal lymph node with PAI myeloma
cells (kindly donated by Jean Langhorne, Francis Crick In-
stitute, UK) using the polyethylene glycol method as previ-
ously described [19]. Hybridomas were selected with HAT
medium and screened by Western-blot using nitrocellulose
membranes containing BBMV. The selected hybridoma
cells were expanded and subcloned by limiting dilution
[20]. Ascitic fluid was produced for each monoclonal anti-
body following the methods described by Harlow & Lane
[20]. Monoclonal antibodies (A-78, A-10 and A-140) were
purified from ascitic fluid using Hi-Trap columns packed
with Protein G Sepharose (Invitrogen). MAb isotypes were
determined with a Pierce Rapid Isotyping Kit-Mouse
(Thermo Scientific) according to the manufacturer’s
instructions.
Production of immune serum against BBMV
One BALB/c mouse was immunized intraperitoneally to
produce immune serum against BBMV as described
[19]. Naive serum was obtained before immunization.
Two weeks after the third immunization the mouse was
cardiac bled and the serum stored at -20 °C. This im-
mune serum is denominated hereafter as IS-BBMV.
Lecona-Valera et al. Parasites & Vectors  (2016) 9:274 Page 2 of 11
Electrophoresis and Western blot analysis
BBMV (150 μg of protein in a preparative gel) were sep-
arated by sodium dodecyl sulfate-polyacrylamide 8 % gel
electrophoresis (SDS-PAGE) [21]. A portion of the gel
was cut and stained with colloidal Coomassie blue G-
250, and the remaining gel was transferred to a nitrocel-
lulose membrane [22]. The membrane was cut into
strips, which were blocked with 0.05 % PBS-tween and
5 % skim milk (blocking solution) for 1 h. Individual
strips were treated with undiluted conditioned medium
from the hybridoma cell cultures and the IS-BBMV di-
luted 1:20,000 in blocking solution (included as positive
control). Membranes were incubated overnight at 4 °C
and treated with goat anti-mouse IgG (Abcam) conju-
gated to horseradish peroxidase (HRP), diluted 1:5000,
at room temperature for 1 h. Bound antibodies were
revealed by a chemiluminescent reaction with the
Immobilon Western kit (Millipore).
Plasmodium berghei parasites
Plasmodium berghei parasites, constitutively expressing
the green fluorescent protein (GFP, kindly provided by
Robert E. Sinden, Imperial College, UK) [23], were cul-
tured in vitro to produce ookinetes [24]. Parasite cul-
tures were centrifuged at 1,000 g for 5 min and the
concentration of ookinetes was determined and adjusted
to 1,000 ookinetes/μl [25] by adding normal mouse
blood (treated exactly as the aforementioned infected
mouse blood) adjusted to 40 % hematocrit using heat-
inactivated fetal bovine serum.
Membrane feeding assay with mAbs
For each experiment, groups of 100 female An. albima-
nus were fed with the GFP ookinetes (1,000 ookinetes/
μl) incubated with purified mAbs A-78, A-10 or A-140
(all of which recognize the BBMV) at indicated concen-
trations. Four experiments were performed, in the first
one, only mAb A-78, A-10, positive and negative con-
trols were included. The positive control was fed with
ookinetes plus 100 μg/ml of mAb 13.1 (anti P28, kindly
donated by R. Sinden, Imperial College, UK), which sig-
nificantly inhibits the transition from ookinetes to oo-
cysts [26]. The negative control was fed with a similar
number of ookinetes but without any antibody. Since
neither mAb A-78 nor mAb A-10 reduced the number
of oocyst formed per midgut in the following three ex-
periments, only mAb A-78 was included as negative
control. Infections were carried out by the standard
Membrane Feeding Assay (MFA) [27]. To increase the
possibility that all mosquitoes would take a full blood
meal, they were starved for at least 5 h before being of-
fered the ookinete preparations (maintained at 37 °C).
Mosquitoes that did not feed were discarded, while
engorged mosquitoes were transferred to an incubator at
21 °C, where they were maintained for 8-10 days and fed
with a solution containing 8 % fructose and 0.5 % para-
aminobenzoic acid [28]. Surviving mosquitoes were dis-
sected and their midguts analyzed using a fluorescent
microscope (Leica DM1000); around 30 mosquitoes per
group that took a meal, survived until the end of each
experiment. The percentage of infected mosquitoes
(prevalence of infection) and the number of oocysts per
mosquito (intensity of infection) were determined.
Statistical analysis
The effect of mAb A-140 was evaluated by counting the
number of oocysts per midgut and the data analyzed. A
zero-inflated Generalized Linear Mixed Model (GLMM)
[26] was employed to compare the numbers of oocysts
per mosquito midgut following infection by using the R
package software.
Characterization of the antigens recognized by mAb A-140
To investigate if the antigen recognized by mAb A-140
was a carbohydrate residue on the proteins, chemical de-
glycosylation was carried out as previously described
[27], with some modifications. Briefly, three nitrocellu-
lose membrane strips that contained BBMV were
washed with 50 mM sodium acetate at pH 4.5 (washing
solution) at RT for 1 h. One strip was incubated with
20 mM sodium periodate in washing solution in the
dark at RT for 1 h. Under these conditions, sodium peri-
odate converts cis-diol groups (on the protein backbone
of all oligosaccharides) into aldehydes, destroying the
carbohydrate residue without altering protein or lipid
epitopes [27]. A second strip was incubated with 1 mM
sodium periodate in washing solution in the dark at 4 °C
for 1 h. Under these conditions sodium periodate de-
stroys N- and O-linked glycans. A third strip, kept in
washing solution under the same conditions but without
the addition of sodium periodate, was used as a control.
All strips were rinsed with three changes of washing so-
lution, incubated with 50 mM sodium borohydride in
PBS at RT for 30 min, and washed three times with PBS.
Finally, BBMV antigens recognized by mAb A-140 were
detected by Western blot analysis. An additional control
included a group of three nitrocellulose membrane strips
containing BBMV that were treated as described and
tested with IS-BBMV.
Identification of the antigens recognized by mAb A-140
To identify the proteins recognized by mAb A-140, we
used an immunoprecipitation assay followed by liquid
chromatography tandem mass spectrometry (LC-MS/MS).
Two hundred midguts that had been frozen in PBS con-
taining 2X protease inhibitor cocktail (Sigma) were thawed
and suspended in 1 ml of cold PBS (also containing 2X
protease inhibitor cocktail), and spun at 500 g for 1 min to
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gently pellet the midguts. After centrifugation the super-
natant was discarded and the midgut pellets were sus-
pended in 1 ml of cold (4 °C) solubilization buffer (50 mM
Tris, 150 mM NaCl, 100 mM EDTA, 1 % NP40 and 1 %
deoxycholic acid) supplemented with the 2X protease in-
hibitor cocktail and homogenized by using an insulin syr-
inge to take in and expel the sample (five times with 2 min
intervals) at 4 °C during 10 min. After centrifugation at
15,000 g for 5 min, the supernatant was discarded and the
pellet (insoluble fraction) was solubilized using 75 μl of
solubilization buffer plus 25 μl of loading buffer (contain-
ing 8 % SDS and 40 % glycerol). The sample was boiled for
5 min and centrifuged at 15,000 g. The supernatant was di-
luted 10-fold with cold solubilization buffer (supplemented
with 2X protease inhibitor cocktail) in order to dilute the
SDS to 0.2 %. A sample of 1 ml (final volume) was cleared
by adding 20 μl of suspended volume of Protein G PLUS-
Agarose beads (Santa Cruz), then incubated on a rocker
platform at 4 °C for 30 min. Afterwards, the sample was
centrifuged at 500 g and 4 °C for 5 min, the supernatant
was transferred to a new Eppendorf tube (1.5 ml), 3 μg of
mAb A-140 were added, and incubation was carried out at
4 °C for 1 h. Then 25 μl of the suspended volume of Pro-
tein G PLUS-Agarose were added, followed by incubation
on a rocker platform and centrifugation at 500 g and 4 °C
for 5 min. The pellet was suspended and washed 4 times
using solubilization buffer supplemented with 2X protease
inhibitor cocktail followed by centrifugation (as aforemen-
tioned). After the final wash, the supernatant was discarded
and the bead pellets were suspended in 40 μl of 1X electro-
phoresis reducing sample buffer and boiled for 5 min.
Finally, the sample was centrifuged at 500 g and 4 °C for
5 min and the supernatant was resolved by SDS-PAGE
(8 %). The gel was visualized by colloidal Coomassie blue
G-250 staining and the bands that corresponded to the
molecular weight of the antigens recognized by mAb A-
140 were cut from the gel for analysis by LC-MS/MS. Gel
slices were cut into 1 × 1 mm pieces prior to de-staining,
reduction and alkylation, tryptic digestion and peptide ex-
traction. The extracted peptides were lyophilized and were
then re-suspended in 2 % acetonitrile, 97.9 % water and
0.1 % formic acid buffer for LC-MS/MS analysis.
LC-MS/MS
In-gel digestion of biological replicate samples from
three independent experiments were analyzed as follows.
Each of the in-gel digestion samples were injected onto
an Agilent LC-MS system comprised of a 1200 LC sys-
tem coupled to a 6520 Q-TOF via an HPLC Chip Cube
interface. The sample was trapped and analyzed using an
Agilent Polaris-HR-Chip-3C18 chip (360 nL, 180 Å C18
trap with a 75 μm i.d., 150 mm length, and 180 Å C18
analytical column). Peptides were loaded onto the en-
richment column automatically by the autosampler
using 97 % solvent A (0.1 % formic acid in water) and
3 % solvent B (0.1 % formic acid in 90 % acetonitrile) at
a flow rate of 1.8 μl/min. Elution of peptides from the
analytical column was performed using a gradient start-
ing at 97 % A at 300 nL/min. The mobile phase was 3-
10 % B for 1 min, 10-40 % B for 19 min, 40-90 % for
3 min, and maintained at 90 % B for 6 min, followed by
re-equilibration of the column with 3 % B for 6 min.
The data dependent (autoMS2) mode was used for MS
acquisition by Agilent 6520 Q-TOF in 2 GHz. Precursor
MS spectra were acquired from m/z 315 to 1700 and the
top 4 peaks were selected for MS/MS analysis. Product
scans were acquired from m/z 50 to 1700 at a scan rate
of 1.5/second. A medium isolation width (∼4 amu) was
used, and a collision energy of slope 3.9 V/100 Da with a
2.9 V offset was applied for fragmentation. A dynamic
exclusion list was applied, with precursors of 0.50 min
excluded after the two MS/MS spectrum was acquired.
Database search
LC-MS/MS raw data were converted to Mascot generic
Format (.mgf) by Agilent MassHunter Qualitative Analysis
B.04.00. Mascot version 2.4.1 was used to search against
three different FASTA databases downloaded from Vector-
Base including Anopheles-albimanus-AalbS1.2 (11,994 se-
quences), Anopheles-darlingi-AdarC3.2 (10,457 sequences),
and Anopheles-gambiae-AgamP3.8 (14,667 sequences), for
peptide sequence assignments using the following parame-
ters: precursor ion mass tolerance of 50 ppm and a frag-
ment ion mass tolerance of 0.2 Daltons. Peptides were
searched using fully tryptic cleavage constraints and up to
two internal cleavage sites were allowed for tryptic diges-
tion. Variable modifications considered were carbamido-
methylation of cysteine and oxidation of methionine
residues. Overall, a protein false discovery rate of less than
1 % with an ion score ≥ 39 was obtained through Mascot
for protein identification.
Results
Three monoclonal antibodies generated against whole
midguts recognized apical BBMV proteins
We consistently obtained around 200 μg of protein from
the BBMV of 1,000 midguts. As expected, these prepara-
tions showed a 5-6 fold increase in aminopeptidase ac-
tivity (data not shown) compared to whole midgut
preparations [28]. One of these reproducible BBMV
preparations (resolved by SDS-PAGE and stained with
colloidal Coomassie blue G-250) revealed the range in
protein molecular masses in this midgut fraction (Fig. 1,
panel A) [29].
We tested supernatants from 27 hybridoma cell cul-
tures by Western blot to: 1) identify hybridomas produ-
cing antibodies that can recognize BBMV, and 2)
determine the repertoire of proteins in the An.
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albimanus midgut BBMV recognized by the antibodies.
Only three mAbs (A-140, A-78 and A-10) recognized
BBMV proteins, and each of these exhibited different
protein banding profiles (Fig. 1, panel B, Lanes 1, 2 and
3). MAb A-140 (IgG1subclass) recognized three proteins
bands (Fig. 1, panel B, Lane 1), one of an apparent mo-
lecular weight of 225–230 kDa and the other two of
~153 and ~136 kDa. MAb A-78 (IgG2b) recognized
three bands of ~60, ~48 and ~42 kDa (Fig. 1, panel B,
Lane 2). MAb A-10 (IgG2b) recognized one protein
band of ~75 kDa. IS-BBMV, included as a positive con-
trol, recognized approximately 16 protein bands from
the BBMV across a broad range of molecular masses
(Fig. 1, panel B, Lane 3). We did not observe any protein
bands below 35 kDa by any mAb after resolving BBMV
proteins in 4-20 % gradient gels prior to immunoblotting
Fig. 1 Immunoblot analysis of monoclonal antibody protein recognition profiles. a BBMV proteins were resolved in SDS-PAGE and stained with colloidal
Coomassie blue. b Western blot analysis of BBMV probed with mAb A-140 (Lane 1), mAb A-78 (Lane 2), mAb A-10 (Lane 3), immune serum generated
against the microvillus extract (IS-BBMV) (Lane 4), and naive serum (Lane 5). c MAbs A-78 and A-10 did not show a significant reduction in the intensity of
infection of P. berghei in An. albimanus mosquitoes. d A representative pooled data is shown from replicate experiments, mAb A-140 significantly reduced
the intensity of infection of mosquitoes (see Table 1 and Additional file 1 for details). e and f Reactivity of mAb A-140 and IS-BBMV following chemical
deglycosylation. Membrane strips were treated with 1 or 20 mM sodium periodate, or untreated (control = C). Molecular masses are indicated in
kilodaltons (kDa)
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(data not shown). No bands were recognized by naive
serum (Fig. 1, panel B, Lane 5) or when primary mAbs
were omitted (data not shown).
MAb A-140 reduced P. berghei oocyst formation
Mosquito groups were fed with P. berghei ookinetes
and one of three An. albimanus mAbs in order to
evaluate the capacity of these antibodies to block or
reduce ookinete midgut invasion. In the first experi-
ment of MFA we observed that mosquitoes that were
fed mAb A-78 and A-10 had similar oocyst intensities
as compared to the negative control group, which
was fed with ookinetes but without any antibody
(Fig. 1c). Therefore, we chose mAb A-78 as the negative
control for the three subsequent independent experiments
of MFA. Oocyst intensity was significantly lower when
using mAb A-140, at both 100 μg/ml (P < 0.0001) and
200 μg/ml (P < 0.0001), compared to mAb A-78 at match-
ing concentrations (Fig. 1d, Table 1, for additional infor-
mation about statistical analysis see Additional file 1). The
mean number of oocysts was similar between mosqui-
toes fed with mAb A-140 (at 200 μg/ml) and the
positive control with anti-P28 mAb13.1 (P = 0.324,
Additional file 1).
MAb A-140 recognized a peptide epitope
A-140 recognized three bands by immunoblot, which may
represent a conserved glycan epitope [6] across several
BBMV glycoproteins. Following treatment with 1 mM or
20 mM sodium periodate, the A-140 recognition profile
remained the same (Fig. 1, panel E) and was similar to that
of the control (un-treated) (Fig. 1, panel E, Lane c). These
data indicate that mAb A-140 does not recognize glycans.
In contrast, the IS-BBMV showed a modified protein pro-
file (at the 20 mM concentration), as was found in the
strip treated with 1 mM sodium periodate compared to
the un-treated strip (Fig. 1, panel F, Lane c). This suggests
that a subset of antibodies in the polyclonal response to
BBMV immunization recognizes glycans.
MAb A-140 immunoprecipitated three main protein
bands from An. albimanus midguts
From three immunoprecipitations of midgut protein ex-
tracts with mAb A-140, we were able to enrich three
protein bands that were visualized by Coomassie (Fig. 2,
Lane 4, arrow head). These bands corresponded to the
protein banding profile for mAb A-140 (Fig. 1, panel B,
Lane 1) in BBMV immunoblots. Additionally, five more
protein bands, between 50-70 kDa and bound to the
Protein G beads, were also enriched following immuno-
precipitation (Fig. 2, Lane 4, arrows). Four of these
bands were also observed in the pre-cleared fraction
(Fig. 2, Lane 3, asterisks), but these proteins did not cor-
respond to any of those detected in BBMV immunoblots
using mAb A-140 (Fig. 1, panel B, Lane 1).
Coomassie-stained bands (Fig. 2, Lane 4, arrowheads)
were excised from the gels of each of the three replicate
immunoprecipitation assays. We identified five proteins
with extremely high Mascot scores (Table 2). Myosin
(AALB007909) was a major component in all replicate
immunoprecipitated samples. This is likely not a con-
taminating protein that bound non-specifically to the
Protein G beads, since no high molecular mass protein
was observed across replicate cleared samples. We also
identified a secreted, heavily glycosylated hypothetical
protein containing an insulin-like growth factor binding
protein (ILGFBP) domain (AALB001083) with a pre-
dicted Mr of 153 kDa. Interestingly, we found three
other cytosolic proteins in addition to myosin: Lingerer
protein (AALB004761), Apaf-1-like killer protein (ARK)
(AALB010165), and another hypothetical protein with
several domains (Calcium binding domain/Kazal-type
serine protease inhibitor domain/Thyroglobulin Type 1
domain) (AALB005141).
MAb A-140 recognized protein bands from Drosophila
and mouse skeletal muscle
To confirm that mAb A-140 recognizes myosin, as op-
posed to a myosin-like protein, we used samples of
whole (without the head) Drosophila melanogaster,
Table 1 Reduction of Plasmodium berghei oocyst intensity in Anopheles albimanus by mAb A-140







(C+) mAb 13.1 (100 μg/ml) 114 54 2.3 (0–25) 83 < 0.0001
(C-) mAb A-78 (100 μg/ml) 104 82 14.2 (0–142) 0 –
(C-) mAb A-78 (200 μg/ml) 59 83 10.8 (0–139) 0 –
mAb A-140 (100 μg/ml) 104 71 4.3 (0–50) 69.2 < 0.0001
mAb A-140 (200 μg/ml) 60 53 2.2 (0–30) 78.9 < 0.0001
Transmission reduction efficiency of mAb A-140 was evaluated at two different doses and compared to anti-P28 mAb 13.1 (positive control, C+) and mAb A-78
(negative control, C-), which was raised against An. albimanus midguts but was determined previously to have no functional activity against the parasite. P-values
as determined by a zero-inflated GLMM statistical methods (see Additional file 1 for details) in comparisons with matched concentrations of mAb A-78 (100 μg/ml
or 200 μg/ml). A representative dataset is shown below from replicate studies. Data correspond to Fig. 1d
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isolated midguts and mouse leg muscle. These samples
were transferred onto membranes and probed with two
antibodies, purified mAb-140 and a commercial anti-
myosin monoclonal antibody that reacts with myosin
(heavy chain) from several mammals (humans, rabbit,
mouse), zebra fish and Drosophila (Millipore, catalog
number 05-716). Unlike what was customarily observed
for An. albimanus midguts (Fig. 3, panel A, Lane 1), mAb
A-140 recognized a prominent protein band of ~ 225–
230 kDa when probed on Drosophila midguts (Fig. 3,
panel A, Lane 2), as well as a protein smear of ~ 200–
250 kDa and one band of ~ 185 kDa (Fig. 3, panel A, Lane
3) when probed on whole Drosophila (without the head).
On mouse skeletal muscle, mAb A-140 recognized (albeit
weakly) one protein band of ~ 204 kDa (Fig. 3, panel A,
lane 4), while the commercial anti-myosin unexpectedly
did not recognize Drosophila or An. albimanus midguts.
However, the latter mAb recognized three protein bands
of ~ 204, 110 and 95 kDa (Fig. 3, panel B, Lane 4) and
recombinant myosin (BIO-RAD molecular weight
standards) (Fig. 3, panel B, Lane 5).
Discussion
We herein report the partial characterization of a mos-
quito midgut molecule that seems to participate in the
process of P. berghei ookinete infection of An. albima-
nus. This molecule was recognized by mAb A-140,
which of the monoclonal antibody tested (including A-
10, A-78 and A-140) was the only one capable of redu-
cing midgut oocyst intensity. These results add new in-
formation to previous studies [6–8, 11, 30–34] using
different parasite/mosquito combinations (including ro-
dent and human malaria parasites) on the effect of
monoclonal and polyclonal antibodies against midgut
molecules participating in midgut invasion.
MAb A-140 was generated from a mouse immunized
with “whole midgut” lysate, and was selected by Western
blot using BBMV. While mAb A-140 recognized pro-
teins in the Drosophila midgut and carcass (without the
head) as well as in mouse skeletal muscle (Fig. 3), it
failed to recognize recombinant myosin. The Western
blot recognition by mAb A-140 of three high molecular
mass protein bands in BBMV preparations confirmed
the presence of the cognate antigens on the apical
membrane.
Fig. 2 Immunoprecipitation of An. albimanus midgut proteins using mAb
A-140. Representative fractions obtained from the immunoprecipitation of
midguts using mAb A-140, analyzed by SDS-PAGE (8 %) and stained with
colloidal Coomassie blue. The whole midgut was solubilized with RIPA
buffer (Lane 1). The insoluble fraction was solubilized with RIPA + SDS 2 %
(Lane 2). The proteins shown are those that bound to Protein G agarose
during the pre-clearing step (Lane 3). The proteins shown are those that
immunoprecipitated with Protein G agarose +mAb A-140 (Lane 4).
Molecular masses are indicated in kDa












AALB007909-PA 6197 250 N Myosin head motor domain
Hypothetical
protein
AALB001083-PA 994 153 Y Insulin-like growth factor binding protein domain, N-terminal domain/4 N-linked
glycosylation sites*/41 O-linked glycosylation sites*
Protein lingerer AALB004761-PA 108 154 N Gly-Ala rich N-terminal domain/Ser-Gly-Ala-Gln rich C-terminal domain
Apaf-1 like killer
protein (ARK)




AALB005141-PA 39 192 N Calcium binding domain/Kazal-type serine protease inhibitor domain/Thyroglobulin
Type 1 domain
*Prediction algorithms: SignalP 3.0was used to predict the presence of a signal peptide (http://www.cbs.dtu.dk/services/SignalP/). NetNGlyc 1.0 and NetOGlyc 4.0
cut-off scores (>0.7 threshold) (http://www.cbs.dtu.dk/services/). GlycoEP (http://www.imtech.res.in/raghava/glycoep/index.html) was also used to predict N- and
O-linked glycan modification sites. The number of sites in common between NetNGlyc/NetOGlyc and GlycoEP are indicated in the table above
Lecona-Valera et al. Parasites & Vectors  (2016) 9:274 Page 7 of 11
The recognition by mAb A-140 of more than one pro-
tein band in BBMV suggested that it recognized carbo-
hydrate isoforms of a single glycoprotein species. While
periodate oxidation of glycans affects carbohydrate anti-
genicity (without affecting the lipids or proteins) (30),
our experiments clearly demonstrated that mAb-A140
recognized peptidic epitopes. Since the BBMV sample
was resolved and transferred to a nitrocellulose mem-
brane prior to periodate treatment, a single polypeptide
target with varying degrees of glycosylation [6] would
nonetheless appear as a ladder of bands [35]. Alterna-
tively, the epitope recognized by mAb A-140 could exist
in more than one glycoprotein [6].
Among the five immunoprecipitated proteins, it was
surprising to find AALB007909 because it corresponds
to the myosin heavy chain. However, this protein has
been previously observed in other insect cells. Immuno-
precipitation of cell surface cadherin from Drosophila
oocyte membranes co-precipitates myosin along with
other cytoskeletal proteins and inner leaflet adaptor pro-
teins that can bridge extracellular proteins through their
transmembrane and/or cytoplasmic tails [36]. Taken to-
gether, these data indicate that the antigen of mAb A-
140 is myosin, localized to the BBMV of the midgut, and
that other midgut proteins co-precipitate with it. This
conclusion is supported by the fact that myosin was
present in all the different excised gel bands spanning
the high molecular mass range proteins on an 8 % Tris-
Glycine gel, and that this protein obtained the highest
mascot score with LC-MS/MS.
The presence of several bands recognized by mAb A-
140 (detected by Western blot) could be interpreted as
cross reactivity with several myosin subtypes. It is possible
that mAb A-140 recognizes an epitope present in type II
myosin, which includes muscular and non-muscular
forms. At present, 15 paralogues of myosin in An. albima-
nus are annotated in VectorBase [37]. The multiple band
recognition by mAb may also be due to degradation prod-
ucts of the 250 kDa myosin (AALB007909).
The inhibitory effect of antibodies may result from a
direct interference of the interaction between ookinetes
and molecules on the mosquito midgut microvilli sur-
face, as has been described by others [7, 8, 10, 34]. This
interference may affect the normal physiology of both
the midgut and the parasite [38, 39] or alternatively, by
blocking attachment of the ookinete to the receptors
present in the midgut glycocalyx or on the microvilli/
plasma membrane [8, 9, 13, 40]. Myosin recognized by
mAb may be involved in mediating individual membrane
component associations, in accordance with the mem-
brane fluid mosaic model [41], or in mediating clusters
of these proteins that are resident on lipid rafts [42];
processes that can directly affect ookinete attachment
and entry.
Non-muscle myosin expressed on the cell surface has
also been shown to promote cell-virus interactions in
the context of microbial pathogenesis. Non-muscle my-
osin heavy chain IIA (NMHC-IIA) and heavy chain II B
(NMHC-IIB) function as receptors for herpes simplex
virus-1 (HSV-1) through their interaction with virus gly-
coproteins B and D [43, 44]. Furthermore, NMHC-IIA,
which is densely aggregated on the surface of nasopha-
ryngeal epithelial cells, mediates the infection of these
cells by Epstein-Barr virus [45]. In a similar manner, we
propose that non-muscle myosin expressed in the mid-
gut microvilli could be used by ookinetes as an uncon-
ventional receptor during the invasion of the midgut.
MAb A-140 binding to myosin may also be indirectly
impacting midgut cell signaling after invasion [46]. An-
other explanation for the inhibitory effect of the antibody
is that once the parasite has penetrated the midgut cell (s)
they become more permeable [34] allowing mAb A-140
to bind to myosin; subsequently inhibiting molecular
events required for parasite traversal of the cell. Finally, it
has been reported that antibodies that affect parasite de-
velopment could pass through the midgut epithelium to
reach the basal labyrinth [47]. We did not test this possi-
bility but it is likely that if the antibodies do make it to the
basal labyrinth that the concentration will be drastically
reduced; resulting in poor transmission-blocking activity.
Another protein immunoprecipitated by mAb A-140
was ILGFBP glycoprotein (AALB001083), which is
Fig. 3 Immunoblot analysis of protein profiles of mAb A-140 and
anti-myosin heavy chain mAb probed on Drosophila and mouse
muscle. a Samples probed with mAb A-140. b Samples probed with
commercial anti-myosin heavy chain mAb. Samples of An. albimanus
midguts (Lane 1), Drosophila midguts (Lane 2), complete Drosophila
(without head) (Lane 3), skeletal muscle from mouse leg (Lane 4), and
the molecular mass ladder, including recombinant myosin (Lane 5).
Molecular masses are indicated in kDa. Note that in Lane 5 anti-myosin
heavy chain reacts with myosin, from the molecular weight standards
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predicted to have at least 4N-linked glycosylation sites
and at least 40 O-linked glycan modifications. High
mannose and complex N-glycans alone are a major class
of glycan posttranslational modifications in mosquitoes
[48]. The presence of 40 and possibly more mucin-type
O-glycans can increase the apparent molecular mass, as
determined by SDS-PAGE, by an additional 27-30 %.
This could explain the difference between the predicted
Mr of 153 kDa and the apparent Mr of 225-230 kDa by
SDS-PAGE and Western blot (Fig. 1, panel B, Lane 1), a
mass range that is not very well resolved by 8 % Tris-
Glycine gels. Additionally, the ILGFBP-related protein
has a signal peptide, but it does not have a predicted
transmembrane anchor or cytoplasmic tail.
The co-precipitation of three cytoplasmic proteins,
ARK (AALB010165), protein lingerer (AALB004761)
and a putative calcium-binding hypothetical protein
(AALB005141), may indicate the interaction of these
molecules with myosin and the cytoskeleton, along with
the ILGFBP-related protein. ARK is the orthologue of D.
melanogaster DARK, which assembles the apoptosome;
a component of the intrinsic cell death pathway. ARK
contains multiple WD repeats in the COOH-terminal
region. The WD domains are involved in protein–pro-
tein interactions [49–51]. In the Aedes aegypti mosquito,
the silencing of ark inhibits apoptosis triggered by
several stimuli [52]. The lingerer protein from D. mela-
nogaster regulates growth and interacts with several
RNA binding proteins in a complex proposed to regulate
translation and/or RNA stability [53]. The putative
hypothetical protein (AALB005141) has several domains
(Table 2) and is predicted to have the capacity to bind to
calcium ions and proteins.
No plausible function of these proteins during midgut
invasion by Plasmodium ookinetes has been identified. It
is likely that the co-precipitation of these proteins was
the result of the multiple protein binding domains
present on lingerer and ARK which ectopically bind to
ILGFBP-related protein and myosin after midgut lysis
and solubilization, prior to immunoprecipitation. It is
also important to note that immunoprecipitation of tar-
get proteins from a cell lysate leaves open the possibility
that ectopic protein-protein interactions would result in
an immunoprecipitated protein repertoire, which would
include artefacts (as opposed to contaminants) following
pull-down.
There is diversity in parasite-midgut interactions. Some
molecules can play major roles, while others may repre-
sent additional/alternative mechanisms or members of a
larger complex. Thus, antibodies for a molecule (anti-
AnAPN1) conserved among several species of anopheline
mosquitoes [29], even at low concentrations, have been
shown to completely inhibit P. falciparum and P. vivax
mosquito infection [54, 55]. Another major difference in
the pathways used by Plasmodium parasites during inva-
sion is exemplified by P. berghei ANKA ookinetes sub-
clones that exhibit differential use of the Enolase Binding
Protein, indicating that this parasite uses more than one
ligand to invade the mosquito midgut [14].
Thus, the incomplete blockade of mosquito infection
achieved by mAb A-140 may reflect its recognition of an
alternative molecule (non-muscle myosin) for invasion.
Additional research is required to identify the specific
epitope recognized by this antibody in myosin. It is also
important to identify its cognate ookinete surface or
secreted protein ligand and to delineate the mechanism
of their involvement in vector host-parasite protein in-
teractions during midgut invasion.
It is paramount to characterize molecules from the
parasite and the mosquito midgut that play a key role in
the mechanisms of midgut invasion as well as the devel-
opment of ookinetes into oocysts, since both events are
essential for parasitic infection and malaria transmission.
In-depth knowledge of such molecules is a prerequisite
for the development of multivalent mosquito-based
transmission-blocking vaccines, which is part of a promis-
ing strategy for malaria elimination. Plasmodium berghei/
An. gambiae models have allowed for the identification of
several mosquito target molecules that play a role in mid-
gut invasion [7, 9, 10]. Nevertheless, care should be taken
when extrapolating murine malaria data to human malaria
biology [8, 13, 14]. Similar to AnAPN1 [54], the orthologs
of AALB007909 are conserved across the major anophel-
ine vectors of malaria parasites. On the other hand, al-
though our results provide indications of the participation
of myosin in Plasmodium ookinete invasion of mosquito
midgut cells, mAb A-140 also recognized a molecular
weight protein similar of that of mouse myosin, raising
the possibility of generating cross reactivity to human my-
osin. In order to include a molecule in vaccine design is
essential to avoid cross reactivity with the host’s mole-
cules. As the heavy chain of myosin are relatively con-
served in all myosin [56] it will be possible that a vaccine
containing mosquito myosin as immunogen will induce
myositis [57]. In this sense, more studies are needed in
order to determine if specific epitopes of anopheline my-
osin exist that are involved in Plasmodium invasion of the
midgut, only in this sense, the inclusion of myosin ortho-
logs could be proposed as vaccine candidates.
Conclusion
In this work we report on a mAb A-140, which recognizes
a protein localized in the brush border membrane vesicles
of Anopheles albimanus midgut that can significantly
decrease P. berghei oocyst intensity. We found that mAb
A-140 immunoprecipitated a complex of five proteins that
was resistant to detergent solubilization from a lysate of
whole mosquito midguts. The most abundant protein
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identified in this complex by LC-MS/MS was myosin. The
antibody also recognized other non-myosin proteins with
molecular weight similar to myosin from Drosophila.
These results provide support for the unconventional in-
volvement of myosin during mosquito midgut invasion by
Plasmodium ookinetes and warrants further molecular
dissection of this transmission-reducing activity.
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